Containers of Ozempic and Wegovy medications are seen at Children's Hospital in Aurora, CO, November 18, 2024. Kevin Mohatt/The Washington Post/Getty Images

Medicare will save approximately $12 billion, or 44%, on 15 high-cost medications as a result of the second round of the program’s drug price negotiations, the Trump administration announced Tuesday evening. The savings are estimated based on what Medicare spent on the medicines last year.

Medicare enrollees are expected to save $685 million on out-of-pocket costs when the prices take effect in 2027.

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss and diabetes treatment, are among the medications that were selected for the second round by the Biden administration just days before it left off

See Full Page